Global T-Cell Immunotherapy Pipeline Analysis, 2016 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments - Research and Markets

DUBLIN--()--The "Global T-Cell Immunotherapy Pipeline Analysis, 2016 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments" report has been added to Research and Markets' offering.

Pipeline Overview

T-cell immunotherapy mainly consists of T-cell receptor (TCR), Tumor-infiltrating lymphocytes (TILs) and Chimeric antigen receptors (CAR) T-cell therapy.

TCR is a complex integral membrane protein that activates T-cells in response to an antigen. Major histocompatibility complex (MHC) molecules activates TCR by the presence of an antigen.

The activation of TCR initiates positive and negative cascades that leads to cellular proliferation, cytokine production, cellular differentiation, and/or activation of induced cell death.

These signaling positive and negative cascades regulate T-cell development, homeostasis, activation, acquisition of effector's functions and apoptosis.

TILs, defined by NCI, the U.S. federal government's principal agency for cancer research and training, as a preparation of cells consisting of autologous tumor infiltrating lymphocytes, that are manipulated in vitro and, upon administration in vivo, re-infiltrate the tumor to initiate tumor cell lysis.

In vitro, TILs are isolated from tumor tissue and cultured with lymphokines such as interleukin-2. The therapeutic TILs are then infused into patients, where after re-infiltration of the tumor, they may induce lysis of tumor cells and tumor regression.

The use of therapeutic TILs is considered as an adoptive immunotherapy.

The high prevalence of cancer and increased safety and efficacy across the globe fuels the extensive research and development for the T-cell immunotherapeutic.

T-cell immunotherapy is emerging as novel and promising approach for the treatment of cancer as it has several advantages over conventional therapies such as very low or no side effects and high specificity.

Key Topics Covered:

1. Research Scope And Methodology

2. Executive Summary

3. Pipeline Outlook

4. Global T-Cell Immunotherapy Pipeline Analysis By Phase (2016)

5 Swot Analysis Of T-Cell Immunotherapy Pipeline

6 Company Profiles

7 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/pwk742/global_tcell

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs, Clinical Trials

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs, Clinical Trials